Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

GlaxoSmithKline has asked the US regulator to expand the licence of its injected lung drug mepolizumab, to include chronic obstructive pulmonary disease (COPD). Under the brand name Nucala ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

Phase 3 trial results Mepolizumab (GSK) Interleukin-5 antagonist monoclonal antibody To reduce exacerbations in adults with chronic obstructive pulmonary disease. Phase 3 trial results ...

There are currently five biologics approved to treat asthma, according to the American Academy of Allergy, Asthma, and Immunology: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab.

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

The CHMP’s recommendation is based on results from the MANDARA phase 3 trial, which compared efficacy and safety of benralizumab vs mepolizumab, the only approved treatment for EGPA, in patients ...

Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...